Femasys Inc. (NASDAQ:FEMY) Short Interest Up 74.5% in March

Femasys Inc. (NASDAQ:FEMY) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 1,150,000 shares, a growth of 74.5% from the February 28th total of 658,900 shares. Currently, 5.9% of the shares of the stock are sold short. Based on an average trading volume of 391,100 shares, the days-to-cover ratio is presently 2.9 days.

Femasys Trading Down 3.4 %

FEMY stock opened at $1.29 on Monday. The business’s 50-day moving average is $1.41 and its 200 day moving average is $1.23. Femasys has a 12-month low of $0.86 and a 12-month high of $1.84. The stock has a market cap of $29.54 million, a price-to-earnings ratio of -1.59 and a beta of -2.85. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. The firm had revenue of $0.58 million during the quarter, compared to the consensus estimate of $1.66 million. On average, sell-side analysts anticipate that Femasys will post -0.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Femasys

Hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in Femasys during the fourth quarter worth $25,000. Jane Street Group LLC acquired a new position in shares of Femasys during the 4th quarter valued at about $30,000. XTX Topco Ltd grew its holdings in shares of Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares during the period. Citadel Advisors LLC acquired a new stake in Femasys during the fourth quarter worth about $45,000. Finally, Northern Trust Corp raised its stake in Femasys by 42.6% during the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after purchasing an additional 37,675 shares during the period. 65.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Femasys in a research report on Friday.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.